CD276 and non-small cell lung carcinoma: Furthermore, potential targets like MAGE-A1 (NCT03198052 and NCT03356808), AMT-253 (NCT05117138), CD276 [(B7-H3): NCT04864821, NCT05190185), and GPC3-transforming growth factor beta (TGF-β; NCT03198546), are under evaluation for CAR-T cell therapy application in NSCLC in clinical trials.